Diabetes drug tested as sepsis treatment
NCT ID NCT07206160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will observe 64 adults with sepsis to see if dapagliflozin, a diabetes medicine, reduces inflammation and improves organ function. Researchers will measure inflammatory markers and track severity of illness and survival. The goal is to learn if this drug could be a helpful addition to standard sepsis care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?